Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. - Wikidata - awgldk - TriplyDB

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

http://www.wikidata.org/entity/Q36269725

about

Prospects for vaccine prevention of meningococcal infection NadA, a novel vaccine candidate of Neisseria meningitidis Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses Meningococcal B vaccine and the vision of a meningitis free world Meningococcal B vaccination strategies and their practical application in Italy How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines Will there ever be a universal Staphylococcus aureus vaccine?Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay The meningococcus and mechanisms of pathogenicity Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.Update on meningococcal disease with emphasis on pathogenesis and clinical management Genotypic and phenotypic modifications of Neisseria meningitidis after an accidental human passage.Global practices of meningococcal vaccine use and impact on invasive disease.Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccines Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein.Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccine Meningococcus.Enterobacterial common antigen.Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteria Biological Activities of Rabbit Immunoglobulin M and Immunoglobulin G Antibodies to Pseudomonas aeruginosa.Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.Prospects offered by genome studies for combating meningococcal disease by vaccination.Immunological and biochemical studies of meningococcal C polysaccharides isolated by diethylaminoethyl chromatography.Cross-protective antigens of Neisseria meningitidis obtained from Slaterus group Y.Classification of Neisseria meningitidis group B into distinct serotypes. II. Extraction of type-specific antigens for serotyping by precipitin techniques.Response of mice to injection of ribosomal fraction from group B Neisseria meningitidis Classification of Neisseria meningitidis group B into distinct serotypes. IV. Preliminary chemical studies on the nature of the serotype antigen.Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response.Antibody responses to meningococcal polysaccharide vaccines Meningococcal disease: treatment and prevention.Meningococcal glycoconjugate vaccines.Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model Meningococcal conjugate vaccines: optimizing global impact.Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7 Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

P2860

Q24537338-F394CB28-C921-4270-B627-41C8108FCE06 Q24675323-E5D0CB2A-BEE1-4E54-8F1C-E10B9CFA534A Q26746887-08395D48-1019-4FF9-9BAE-2422B5DC91AA Q26770696-AB121F1B-D175-4769-866D-C266A0292B68 Q26770699-9B2C3C84-6105-468E-90E1-D9BEB3A54632 Q26782340-DEFBEAD1-1B57-44AC-A8B1-134111CB1A02 Q26824837-93F93A76-64F3-4DED-A609-BAB903ED0814 Q28344521-1BE11178-12D6-49D7-8BBE-88B07A862A5A Q33626434-763789A1-2EB1-4437-B213-E87B60741C59 Q33754255-1FF7DC6A-79B7-461B-A0EB-4CBDC0ECA011 Q33767903-73A073C3-3718-4923-AC92-07463CBB4B0C Q33812435-0DE7B025-477B-4FE5-96C7-E80BDBACF95E Q33840768-6F154BA6-004E-4668-8173-458858A2E0BC Q33850840-9D509A5A-97DF-4890-8B01-D5A07F9180EB Q33870163-A345B575-956F-47AA-A1DA-92354941A53A Q34001933-02CF2862-079A-46B3-A601-41AB77C22709 Q34003052-70BA287D-AF4D-4AD7-B155-4D348A6D485A Q34051257-5E5E81D5-10F2-463A-8D0A-3AB1DEE94FB3 Q34072013-44753560-C4C9-4AE7-8869-0D6F731D4993 Q34145007-FEA1405E-4737-4FB3-9D33-8764A73F5C1A Q34160670-593D3AC8-F190-4DF0-AA6D-DD1DB33218D4 Q34260060-65829EA1-92ED-4270-B883-BEBA0BF0DAB0 Q34320259-057B726A-19F2-44B1-8D6C-B78D24D6A7EF Q34333219-97AAFC32-254E-4D95-A386-BB44B793A651 Q34355276-7923E5B5-6E94-43A2-825C-309A607C426B Q34399467-A814DF77-8FD1-4F84-83D7-31F01B9F747A Q34471107-F74BEBAB-C175-4933-A936-22D061B56DA5 Q34475722-0BA743D6-2A87-4089-8AD8-89DAD2724CDA Q34477200-2F032806-5705-4E79-A714-8859546EDD0B Q34479785-6ECADAD9-029B-4ACB-81A4-C047995C4C96 Q34483171-8E5E75FC-070E-4598-A54B-A6A101B4877A Q34496639-7DD1327D-3177-43F9-AC8F-25650BE3CDEC Q35055030-673C7142-BEE4-4E0C-B34C-7D35A57606BB Q35194824-6C4D8CCA-2AFF-4100-AE49-140EBE9F8A11 Q35224131-6EAA0365-B433-4892-91D9-BA24CB1ACB3F Q35229074-A5BCF4A5-B615-47FB-A309-1ADCF6EC548F Q35427366-7D4B58ED-C058-4539-B5BC-3A599C04BAC1 Q35547767-F7EC2C9E-CA64-4512-9503-E924DC778830 Q35783511-ECFEDA3C-130E-4269-9087-A6B66F056E84 Q35901911-F1B5EEB1-495B-45E8-AE03-17EE8C350711

P2860

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

http://www.wikidata.org/entity/Q36269725

description

1969 nî lūn-bûn

@nan

1969年の論文

@ja

1969年学术文章

@wuu

1969年学术文章

@zh-cn

1969年学术文章

@zh-hans

1969年学术文章

@zh-my

1969年学术文章

@zh-sg

1969年學術文章

@yue

1969年學術文章

@zh

1969年學術文章

@zh-hant

name

Human immunity to the meningoc ...... ccharides in human volunteers.

@ast

Human immunity to the meningoc ...... ccharides in human volunteers.

@en

type

label

Human immunity to the meningoc ...... ccharides in human volunteers.

@ast

Human immunity to the meningoc ...... ccharides in human volunteers.

@en

prefLabel

Human immunity to the meningoc ...... ccharides in human volunteers.

@ast

Human immunity to the meningoc ...... ccharides in human volunteers.

@en

P1433

Q36269725-D7694227-05EA-4E99-98C6-CA8CA94800E2

P1476

Q36269725-6D37420C-C946-4867-AA66-9E1BA455A04A

P2093

Q36269725-00DAA638-4EF1-41F8-988C-E2ACE38DE0D6

Q36269725-32CBFA49-59D7-441D-A375-695207945942

Q36269725-D8F1CA1E-1B15-4B0D-AC09-7E2B992BA519

P2860

Q36269725-071F02CC-B89F-4383-9B09-9D56624CAC25

Q36269725-20A8236A-4D29-4724-9EA4-4D70AE101E59

Q36269725-3228105C-7A6C-424C-990B-8DA667024A75

Q36269725-3D562F3F-69B8-4719-A2E7-2BD0C6C81991

Q36269725-436CFF09-7DB6-4E2A-97FE-9A4E7A079A72

Q36269725-590B68A8-55BB-4927-A92B-6731682AD0E6

Q36269725-5E7DBD24-87AA-440F-AC1C-91CBB3042166

Q36269725-C5B29F8D-61A8-40C4-8E66-2DFE33267747

Q36269725-CAC3DDC1-2973-41A9-88BA-849012AA49F0

Q36269725-D0340380-F5F6-4D24-BD3C-8EC9F50C1B0C

P304

Q36269725-06FB8B3B-70FE-4742-9FF3-F294CA952352

P31

Q36269725-EF0CDE1F-C117-4CC2-BB86-959E5BDE7229

P356

Q36269725-4498A91B-8C7B-4865-AED5-60994FFCB30A

P407

Q36269725-ACEBD589-CA9B-4B7A-922E-EE4F1B624BEC

P433

Q36269725-F2584B8B-AF64-4F48-BC09-21984482A51F

P478

Q36269725-0A6D3C67-043A-4441-8A4E-95A1F8CB614C

P577

Q36269725-241CF879-545B-4DD3-A515-5D0240265B77

P5875

Q36269725-EBBE0B89-4691-4E15-9372-6376DDDCE4B2

P698

Q36269725-71494727-8B50-49BD-9DCA-EE65A483FE5E

P921

Q36269725-8106E5A7-082D-46C0-807C-78C20B221EEC

P932

Q36269725-3949AC8A-4932-433A-9696-E435ABC1C6C7

P356

P1433

Journal of Experimental Medicine

P1476

Human immunity to the meningoc ...... ccharides in human volunteers.

@en

P2093

Artenstein MS

http://www.w3.org/2001/XMLSchema#string

Goldschneider I

http://www.w3.org/2001/XMLSchema#string

Gotschlich EC

http://www.w3.org/2001/XMLSchema#string

P2860

PERTUSSIS VACCINE TESTING FOR FREEDOM-FROM-TOXICITY.

Human immunity to the meningococcus. I. The role of humoral antibodies.

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Human immunity to the meningococcus. II. Development of natural immunity

A somatic antigen vaccine for the prevention of meningococcal cerebrospinal meningitis.

A defined agar medium for genetic transformation of Neisseria meningitidis.

STUDIES ON MENINGOCOCCAL INFECTION : XIII. CORRELATION BETWEEN ANTIPOLYSACCHARIDE AND THE ANTIBODY WHICH PROTECTS MICE AGAINST INFECTION WITH TYPE I MENINGOCOCCI.

The effect of bacterial endotoxins on the water intake and body weight of mice.

PREPARATION OF THE TYPE-SPECIFIC POLYSACCHARIDE OF THE TYPE I MENINGOCOCCUS AND A STUDY OF ITS EFFECTIVENESS AS AN ANTIGEN IN HUMAN BEINGS.

CHEMICAL STUDIES ON BACTERIAL AGGLUTINATION : VII. A QUANTITATIVE STUDY OF THE TYPE SPECIFIC AND GROUP SPECIFIC ANTIBODIES IN ANTIMENINGOCOCCAL SERA OF VARIOUS SPECIES AND THEIR RELATION TO MOUSE PROTECTION.

P304

1367-1384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.129.6.1367

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

1969-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277530915

http://www.w3.org/2001/XMLSchema#string

P698

4977283

http://www.w3.org/2001/XMLSchema#string

P921

polysaccharides

P932

2138657

http://www.w3.org/2001/XMLSchema#string